Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 297-300

Karger

Access to resources Recommend Favorite

BRAF,NRAS and MC1R status in a prospective series of primary cutaneous melanoma

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 4, 2015-04 ,pp. : 1128-1131

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 8, 2015-08 ,pp. : 1530-1538

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 160-169

John Wiley & Sons Inc

Access to resources Recommend Favorite